(TheNewswire)
Vancouver, British Columbia - TheNewswire - January 04, 2022 -Blackhawk Growth Corp. (CSE:BLR ) (CNSX:BLR.CN)(OTC:BLRZF) ( Frankfurt:0JJ) (the “ Corporation ” or “ Blackhawk ”), ispleased to announce that its wholly owned subsidiary, MindBioTherapeutics Pty Ltd (“ MindBio ”), is developing a proprietarytechnology and a new scientific method to objectively test theeffectiveness and delivery of microdosing psychedelicmedicines.
MindBio is currently undertaking the world’s firstclinical trial of its kind and the data will be used to develop newtechnology to assist with delivering psychedelic medicines. Thetechnology will be developed and then tested and enhanced inMindBio’s Phase 2 clinical trials. The novel technology will collectdata from participants in microdosing clinical trials with the aim todetermine an optimal microdose for individual patients.
In its Phase 1 clinical trial microdosing LSD (LysergicAcid Diethylamide), MindBio is microdosing LSD to 80 healthyparticipants who take the drug at home in the same way that they wouldtake any other medication. MindBio’s strategy of microdosing ofpsychedelic medicines administered using smart drug deliverytechnology will lead to a highly scalable method for treating mentalhealth disorders. With preparation work underway, MindBio will conductits Phase 2 clinical trials in early 2022 microdosing patients withmajor depressive disorder and in patients with late-stagecancer.
“MindBio’s leadership in clinical trials ofpsychedelic medicines has the potential to also lead to the creationof new drug delivery technologies that would allow psychedelicmedicines to be administered at scale”, says Frederick Pels, CEO ofBlackhawk Growth. “Using the data from our Phase 1 clinical trialsto develop and test the drug delivery technology in our Phase 2clinical trials will help accelerate our pathway tocommercialization.”
-
https://www.beckleyfoundation.org/2018/06/13/psychedelics-promote-neural-plasticity/
-
https://www.cell.com/cell-reports/fulltext/S2211-1247(18)30755-1
About Blackhawk Growth
Blackhawk is an investment holding company looking tocreate substantial value for its shareholders through the acquisitionand development of high growth companies. It has focused itsinvestments in the health, cannabis and cannabidiol industries in bothCanada and the United States. Its portfolio of companies includes SacPharma, LeichtMind Clinics, Trip Pharma, Noble Hemp, Spaced Food,NuWave Foods, Digital Mind Therapeutics and MindBio Therapeutics –as well as an equity position in Gaia Grow Corp. (CSE:GAIA).
The Company diligently posts updates through videosfrom the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A
Please join the conversation on our Blackhawk groupsupporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com .
For further information please contact:
Frederick Pels, Chief ExecutiveOfficer
(403)-991-7737
fred@ blackhawkgrowth.com
Cautionary NoteRegarding Forward-Looking Statement
All statements in this pressrelease, other than statements of historical fact, are “forward-looking information”with respect to the Company within the meaning of applicablesecurities laws, including with respect to transaction and futureoperations of MindBio Therapeutics Pty Ltd. The Company providesforward-looking statements for the purpose of conveying informationabout current expectations and plans relating to the future andreaders are cautioned that such statements may not be appropriate forother purposes. By its nature, this information is subject to inherentrisks and uncertainties that may be general or specific and which giverise to the possibility that expectations, forecasts, predictions,projections or conclusions will not prove to be accurate, thatassumptions may not be correct and that objectives, strategic goalsand priorities will not be achieved. These risks and uncertaintiesinclude but are not limited those identified and reported in theCompany’s public filings under the Company’s SEDAR profile atwww.sedar.com. Although the Company has attempted to identifyimportant factors that could cause actual actions, events or resultsto differ materially from those described in forward-lookinginformation, there may be other factors that cause actions, events orresults not to be as anticipated, estimated or intended. There can beno assurance that such information will prove to be accurate as actualresults and future events could differ materially from thoseanticipated in such statements. The Company disclaims any intention orobligation to update or revise any forward-looking information,whether as a result of new information, future events or otherwiseunless required by law.
Copyright (c) 2022 TheNewswire - All rights reserved.